Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 10 310 ILS 6.6% Market Closed
Market Cap: 116.1B ILS

TEVA's latest stock split occurred on Jun 27, 2004

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 27, 2004. This was TEVA's 2nd stock split, following the previous one in Dec 11, 2002.

Last Splits:
Jun 27, 2004
2-for-1
Dec 11, 2002
2-for-1
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After
Last Splits:
Jun 27, 2004
2-for-1
Dec 11, 2002
2-for-1

Teva Pharmaceutical Industries Ltd
Stock Splits History

TEVA Stock Splits Timeline
Jun 27, 2004
Jun 27, 2004
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After
Dec 11, 2002
Dec 11, 2002
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
5 435.2 ILS
Overvaluation 47%
Intrinsic Value
Price
Back to Top